Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV. Changes in drug mechanism across evolutionary boundaries

Quinolones are the most active oral antibacterials in clinical use and act by increasing DNA cleavage mediated by prokaryotic type II topoisomerases. Although topoisomerase IV appears to be the primary cytotoxic target for most quinolones in Gram-positive bacteria, interactions between the enzyme an...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of biological chemistry 1999-12, Vol.274 (50), p.35927-35932
Hauptverfasser: Anderson, V E, Zaniewski, R P, Kaczmarek, F S, Gootz, T D, Osheroff, N
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 35932
container_issue 50
container_start_page 35927
container_title The Journal of biological chemistry
container_volume 274
creator Anderson, V E
Zaniewski, R P
Kaczmarek, F S
Gootz, T D
Osheroff, N
description Quinolones are the most active oral antibacterials in clinical use and act by increasing DNA cleavage mediated by prokaryotic type II topoisomerases. Although topoisomerase IV appears to be the primary cytotoxic target for most quinolones in Gram-positive bacteria, interactions between the enzyme and these drugs are poorly understood. Therefore, the effects of ciprofloxacin on the DNA cleavage and religation reactions of Staphylococcus aureus topoisomerase IV were characterized. Ciprofloxacin doubled DNA scission at 150 nM drug and increased cleavage approximately 9-fold at 5 microM. Furthermore, it dramatically inhibited rates of DNA religation mediated by S. aureus topoisomerase IV. This inhibition of religation is in marked contrast to the effects of antineoplastic quinolones on eukaryotic topoisomerase II, and suggests that the mechanistic basis for quinolone action against type II topoisomerases has not been maintained across evolutionary boundaries. The apparent change in quinolone mechanism was not caused by an overt difference in the drug interaction domain on topoisomerase IV. Therefore, we propose that the mechanistic basis for quinolone action is regulated by subtle changes in drug orientation within the enzyme.drug.DNA ternary complex rather than gross differences in the site of drug binding.
doi_str_mv 10.1074/jbc.274.50.35927
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_17455773</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17455773</sourcerecordid><originalsourceid>FETCH-LOGICAL-p238t-46031f004d5d72b486f4551a330933676b1b71437009fa9534a50391d1290b2e3</originalsourceid><addsrcrecordid>eNo1kMtOwzAURL0A0VLYs0JesWvwM46XVXlVqkCIxzayE6d1lcTBjpH6E3wzBspsRhqNju4dAC4wyjAS7Hqnq4wIlnGUUS6JOAJThAieS8KLCTgNYYeSmMQnYIIRLzgTcgq-nqPtXet6E6Dtt1bbEd48LqA3rd2o0boedqa2ajQ11Hv4Mqphu29d5aoqBqiiN8lGNzgbXGe8Cgau3jO43Kp-84uEtY-bxKhSYkMHVeVdCNB8ujb-4JXfQ-1iXytvTTgDx41qgzk_-Ay83d2-Lh_m66f71XKxng-EFuOc5YjiJn1T81oQzYq8YZxjRSmSlOYi11gLzKhASDZKcsoUR1TiGhOJNDF0Bq7-uIN3H9GEsexsqEzbqt64GEosEk8ImoqXh2LUaYhy8LZLJ5f_C9Jvfo1zCw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17455773</pqid></control><display><type>article</type><title>Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV. Changes in drug mechanism across evolutionary boundaries</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Anderson, V E ; Zaniewski, R P ; Kaczmarek, F S ; Gootz, T D ; Osheroff, N</creator><creatorcontrib>Anderson, V E ; Zaniewski, R P ; Kaczmarek, F S ; Gootz, T D ; Osheroff, N</creatorcontrib><description>Quinolones are the most active oral antibacterials in clinical use and act by increasing DNA cleavage mediated by prokaryotic type II topoisomerases. Although topoisomerase IV appears to be the primary cytotoxic target for most quinolones in Gram-positive bacteria, interactions between the enzyme and these drugs are poorly understood. Therefore, the effects of ciprofloxacin on the DNA cleavage and religation reactions of Staphylococcus aureus topoisomerase IV were characterized. Ciprofloxacin doubled DNA scission at 150 nM drug and increased cleavage approximately 9-fold at 5 microM. Furthermore, it dramatically inhibited rates of DNA religation mediated by S. aureus topoisomerase IV. This inhibition of religation is in marked contrast to the effects of antineoplastic quinolones on eukaryotic topoisomerase II, and suggests that the mechanistic basis for quinolone action against type II topoisomerases has not been maintained across evolutionary boundaries. The apparent change in quinolone mechanism was not caused by an overt difference in the drug interaction domain on topoisomerase IV. Therefore, we propose that the mechanistic basis for quinolone action is regulated by subtle changes in drug orientation within the enzyme.drug.DNA ternary complex rather than gross differences in the site of drug binding.</description><identifier>ISSN: 0021-9258</identifier><identifier>DOI: 10.1074/jbc.274.50.35927</identifier><identifier>PMID: 10585479</identifier><language>eng</language><publisher>United States</publisher><subject>Anti-Infective Agents - pharmacology ; Biological Evolution ; Ciprofloxacin - pharmacology ; DNA Damage ; DNA religation ; DNA Repair - drug effects ; DNA Topoisomerase IV ; DNA Topoisomerases, Type II - drug effects ; DNA Topoisomerases, Type II - genetics ; DNA Topoisomerases, Type II - metabolism ; Escherichia coli - enzymology ; Etoposide - pharmacology ; Fluoroquinolones ; Gram-Positive Bacteria - drug effects ; Kinetics ; Quinolones - pharmacology ; Staphylococcus aureus ; Staphylococcus aureus - enzymology ; Staphylococcus aureus - genetics</subject><ispartof>The Journal of biological chemistry, 1999-12, Vol.274 (50), p.35927-35932</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10585479$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Anderson, V E</creatorcontrib><creatorcontrib>Zaniewski, R P</creatorcontrib><creatorcontrib>Kaczmarek, F S</creatorcontrib><creatorcontrib>Gootz, T D</creatorcontrib><creatorcontrib>Osheroff, N</creatorcontrib><title>Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV. Changes in drug mechanism across evolutionary boundaries</title><title>The Journal of biological chemistry</title><addtitle>J Biol Chem</addtitle><description>Quinolones are the most active oral antibacterials in clinical use and act by increasing DNA cleavage mediated by prokaryotic type II topoisomerases. Although topoisomerase IV appears to be the primary cytotoxic target for most quinolones in Gram-positive bacteria, interactions between the enzyme and these drugs are poorly understood. Therefore, the effects of ciprofloxacin on the DNA cleavage and religation reactions of Staphylococcus aureus topoisomerase IV were characterized. Ciprofloxacin doubled DNA scission at 150 nM drug and increased cleavage approximately 9-fold at 5 microM. Furthermore, it dramatically inhibited rates of DNA religation mediated by S. aureus topoisomerase IV. This inhibition of religation is in marked contrast to the effects of antineoplastic quinolones on eukaryotic topoisomerase II, and suggests that the mechanistic basis for quinolone action against type II topoisomerases has not been maintained across evolutionary boundaries. The apparent change in quinolone mechanism was not caused by an overt difference in the drug interaction domain on topoisomerase IV. Therefore, we propose that the mechanistic basis for quinolone action is regulated by subtle changes in drug orientation within the enzyme.drug.DNA ternary complex rather than gross differences in the site of drug binding.</description><subject>Anti-Infective Agents - pharmacology</subject><subject>Biological Evolution</subject><subject>Ciprofloxacin - pharmacology</subject><subject>DNA Damage</subject><subject>DNA religation</subject><subject>DNA Repair - drug effects</subject><subject>DNA Topoisomerase IV</subject><subject>DNA Topoisomerases, Type II - drug effects</subject><subject>DNA Topoisomerases, Type II - genetics</subject><subject>DNA Topoisomerases, Type II - metabolism</subject><subject>Escherichia coli - enzymology</subject><subject>Etoposide - pharmacology</subject><subject>Fluoroquinolones</subject><subject>Gram-Positive Bacteria - drug effects</subject><subject>Kinetics</subject><subject>Quinolones - pharmacology</subject><subject>Staphylococcus aureus</subject><subject>Staphylococcus aureus - enzymology</subject><subject>Staphylococcus aureus - genetics</subject><issn>0021-9258</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kMtOwzAURL0A0VLYs0JesWvwM46XVXlVqkCIxzayE6d1lcTBjpH6E3wzBspsRhqNju4dAC4wyjAS7Hqnq4wIlnGUUS6JOAJThAieS8KLCTgNYYeSmMQnYIIRLzgTcgq-nqPtXet6E6Dtt1bbEd48LqA3rd2o0boedqa2ajQ11Hv4Mqphu29d5aoqBqiiN8lGNzgbXGe8Cgau3jO43Kp-84uEtY-bxKhSYkMHVeVdCNB8ujb-4JXfQ-1iXytvTTgDx41qgzk_-Ay83d2-Lh_m66f71XKxng-EFuOc5YjiJn1T81oQzYq8YZxjRSmSlOYi11gLzKhASDZKcsoUR1TiGhOJNDF0Bq7-uIN3H9GEsexsqEzbqt64GEosEk8ImoqXh2LUaYhy8LZLJ5f_C9Jvfo1zCw</recordid><startdate>19991210</startdate><enddate>19991210</enddate><creator>Anderson, V E</creator><creator>Zaniewski, R P</creator><creator>Kaczmarek, F S</creator><creator>Gootz, T D</creator><creator>Osheroff, N</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7QL</scope><scope>7TM</scope><scope>C1K</scope></search><sort><creationdate>19991210</creationdate><title>Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV. Changes in drug mechanism across evolutionary boundaries</title><author>Anderson, V E ; Zaniewski, R P ; Kaczmarek, F S ; Gootz, T D ; Osheroff, N</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p238t-46031f004d5d72b486f4551a330933676b1b71437009fa9534a50391d1290b2e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Anti-Infective Agents - pharmacology</topic><topic>Biological Evolution</topic><topic>Ciprofloxacin - pharmacology</topic><topic>DNA Damage</topic><topic>DNA religation</topic><topic>DNA Repair - drug effects</topic><topic>DNA Topoisomerase IV</topic><topic>DNA Topoisomerases, Type II - drug effects</topic><topic>DNA Topoisomerases, Type II - genetics</topic><topic>DNA Topoisomerases, Type II - metabolism</topic><topic>Escherichia coli - enzymology</topic><topic>Etoposide - pharmacology</topic><topic>Fluoroquinolones</topic><topic>Gram-Positive Bacteria - drug effects</topic><topic>Kinetics</topic><topic>Quinolones - pharmacology</topic><topic>Staphylococcus aureus</topic><topic>Staphylococcus aureus - enzymology</topic><topic>Staphylococcus aureus - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Anderson, V E</creatorcontrib><creatorcontrib>Zaniewski, R P</creatorcontrib><creatorcontrib>Kaczmarek, F S</creatorcontrib><creatorcontrib>Gootz, T D</creatorcontrib><creatorcontrib>Osheroff, N</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nucleic Acids Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>The Journal of biological chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Anderson, V E</au><au>Zaniewski, R P</au><au>Kaczmarek, F S</au><au>Gootz, T D</au><au>Osheroff, N</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV. Changes in drug mechanism across evolutionary boundaries</atitle><jtitle>The Journal of biological chemistry</jtitle><addtitle>J Biol Chem</addtitle><date>1999-12-10</date><risdate>1999</risdate><volume>274</volume><issue>50</issue><spage>35927</spage><epage>35932</epage><pages>35927-35932</pages><issn>0021-9258</issn><abstract>Quinolones are the most active oral antibacterials in clinical use and act by increasing DNA cleavage mediated by prokaryotic type II topoisomerases. Although topoisomerase IV appears to be the primary cytotoxic target for most quinolones in Gram-positive bacteria, interactions between the enzyme and these drugs are poorly understood. Therefore, the effects of ciprofloxacin on the DNA cleavage and religation reactions of Staphylococcus aureus topoisomerase IV were characterized. Ciprofloxacin doubled DNA scission at 150 nM drug and increased cleavage approximately 9-fold at 5 microM. Furthermore, it dramatically inhibited rates of DNA religation mediated by S. aureus topoisomerase IV. This inhibition of religation is in marked contrast to the effects of antineoplastic quinolones on eukaryotic topoisomerase II, and suggests that the mechanistic basis for quinolone action against type II topoisomerases has not been maintained across evolutionary boundaries. The apparent change in quinolone mechanism was not caused by an overt difference in the drug interaction domain on topoisomerase IV. Therefore, we propose that the mechanistic basis for quinolone action is regulated by subtle changes in drug orientation within the enzyme.drug.DNA ternary complex rather than gross differences in the site of drug binding.</abstract><cop>United States</cop><pmid>10585479</pmid><doi>10.1074/jbc.274.50.35927</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0021-9258
ispartof The Journal of biological chemistry, 1999-12, Vol.274 (50), p.35927-35932
issn 0021-9258
language eng
recordid cdi_proquest_miscellaneous_17455773
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
subjects Anti-Infective Agents - pharmacology
Biological Evolution
Ciprofloxacin - pharmacology
DNA Damage
DNA religation
DNA Repair - drug effects
DNA Topoisomerase IV
DNA Topoisomerases, Type II - drug effects
DNA Topoisomerases, Type II - genetics
DNA Topoisomerases, Type II - metabolism
Escherichia coli - enzymology
Etoposide - pharmacology
Fluoroquinolones
Gram-Positive Bacteria - drug effects
Kinetics
Quinolones - pharmacology
Staphylococcus aureus
Staphylococcus aureus - enzymology
Staphylococcus aureus - genetics
title Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV. Changes in drug mechanism across evolutionary boundaries
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T22%3A41%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Quinolones%20inhibit%20DNA%20religation%20mediated%20by%20Staphylococcus%20aureus%20topoisomerase%20IV.%20Changes%20in%20drug%20mechanism%20across%20evolutionary%20boundaries&rft.jtitle=The%20Journal%20of%20biological%20chemistry&rft.au=Anderson,%20V%20E&rft.date=1999-12-10&rft.volume=274&rft.issue=50&rft.spage=35927&rft.epage=35932&rft.pages=35927-35932&rft.issn=0021-9258&rft_id=info:doi/10.1074/jbc.274.50.35927&rft_dat=%3Cproquest_pubme%3E17455773%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17455773&rft_id=info:pmid/10585479&rfr_iscdi=true